news

  • 9 May 2016
    Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology

    Axonics Modulation Technologies, Inc., developer of the first rechargeable implantable Sacral Neuromodulation System (SNM) for the treatment of urinary and fecal dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics six U.S. patents relating to implantable neuromodulation technology and recharging systems.

    “The rapid grant of six U.S. patents demonstrates the level of ingenuity incorporated into the Axonics technology platform and our commitment to developing a robust patent portfolio in conjunction with our innovations,” said Raymond W. Cohen, Axonics Chief Executive Officer. “With more than forty-five issued U.S. and OUS patents already in our portfolio, and seventy-five additional pending patent applications, the recent string of patent grants represents the first wave in what we expect to be a sustained expansion of our intellectual property presence in key markets around the globe.”

    The U.S. patents granted over the past twelve months include US 9,044,614, US 9,308,378, US 9,221,119, US 9,166,441, US 9,205,273 and US 9,155,901. The Axonics patent portfolio represents technology developed under license from the Alfred Mann Foundation and technology internally developed by Axonics.